HSPA5 and acute myeloid leukemia: In contrast to control CAR T cells, GRP78-CAR T-cell treatments released significantly higher levels of cytokine IFN-γ to the supernatant, which indicates that GRP78-CAR T cells specifically elicit immune cytotoxicity to patients’ AML blasts (Figure 3B).